Novavax Leadership Under Fire After Shareholder Revolt at Annual Meeting

RALEIGH, NC – June 24, 2026

Biotechnology firm Novavax is confronting a significant challenge from its own investors, after its recent annual meeting revealed deep-seated dissatisfaction with the company's leadership and compensation practices. While all formal resolutions passed, the voting tally showed a stark rebellion, giving potent ammunition to its largest shareholder, activist investor Shah Capital, which is now intensifying its campaign for a strategic overhaul.

In a sharply worded statement following the June 18th meeting, Shah Capital founder Himanshu Shah labeled the results a “WAKE-UP call for Novavax’s leadership.” The firm argues the vote validates its long-standing criticisms of “chronic operational shortcomings, weak execution, excessive administrative/consulting costs and the destruction of shareholder value,” setting the stage for a contentious period as management is pressured to respond.

A Vote of No Confidence?

On the surface, Novavax’s management secured a victory at its Annual General Meeting (AGM). All board members were re-elected, and all company proposals were approved. However, a closer look at the numbers, detailed in the company’s subsequent SEC filings, paints a picture of profound shareholder dissent.

The advisory "say-on-pay" proposal, which concerns the approval of the executive compensation package, was met with extraordinary opposition. Nearly half of the votes cast—approximately 48.8%—were against the package. This level of disapproval is rare, especially when external proxy advisory firms had issued a "For Recommendation," and it signals a clear disconnect between the board's view of performance-based pay and shareholder sentiment.

The discontent extended to the board itself. Three Class I directors, including CEO John C. Jacobs, faced significant pushback. Votes against their re-election ranged from approximately 38% to 41%, an unusually high figure for incumbent directors. Shah Capital described this as “unprecedented opposition,” interpreting it as a direct rebuke of the current board's oversight and strategic direction. "Shareholders are clearly infuriated by a leadership team that has overseen chronic operational shortcomings," Mr. Shah stated in his public comments.

This groundswell of opposition was not accidental. Shah Capital, which holds a 9% stake in the company, had publicly declared its intention to vote against these key proposals in April, urging fellow shareholders to join them. While the firm stopped short of a costly formal proxy fight, its campaign to rally dissent appears to have resonated powerfully with a large portion of the investor base.

Performance vs. Potential

The conflict hinges on two competing narratives about Novavax. Management points to recent progress, including a first-quarter 2026 earnings report that significantly beat analyst expectations on both revenue and earnings per share. The company highlights its strategic partnerships—a $1.2 billion alliance with Sanofi and a non-exclusive licensing deal with Pfizer for its Matrix-M vaccine adjuvant—as proof of a forward-looking strategy that leverages its core scientific assets.

Shah Capital, however, argues this recent positive data is overshadowed by a longer-term pattern of value destruction. The activist firm points to a multi-year decline in share price, significant shareholder dilution as the number of outstanding shares nearly doubled, and a dwindling cash position. The central pillar of their frustration is the market performance of Nuvaxovid, the company's protein-based COVID-19 vaccine. Despite being what Shah calls the "best-in-class covid vaccine on efficacy and safety," it captured a minuscule market share. The activist investor finds it "completely unfathomable and frankly unacceptable" that the vaccine has failed to compete more effectively against mRNA rivals.

Furthermore, the firm has expressed impatience with perceived delays in the company's pipeline, specifically the Phase 3 trial for a combination COVID-19/influenza vaccine, a cornerstone of the Sanofi partnership. Shah Capital believes management’s projection of capturing 10% of the U.S. COVID vaccine market in 2026 is unambitious, arguing that a target of over 30% is achievable with proper execution. This clash over what constitutes success—short-term financial beats versus long-term market dominance and strategic execution—lies at the heart of the shareholder unrest.

The Activist's Playbook

Shah Capital's campaign against Novavax is not new, but it has entered a new phase of intensity. The investment firm has a history of engaging with the company, having previously pushed for a sale in 2025 and criticized what it called a "failed strategy." Their activism quieted after the Sanofi deal was announced in 2024, but it roared back to life this spring.

The firm's demands are clear and consistent: a smaller, more accountable board with shareholder representation; aggressive cost-cutting, particularly within a "top-heavy" management structure; a more pragmatic business strategy focused on profitability; and an immediate share buyback program to capitalize on what it sees as an "extremely undervalued" stock.

The results of the AGM suggest this playbook is working. By successfully turning a significant portion of the shareholder base against management's key proposals, Shah Capital has demonstrated that its concerns are widely shared. This public validation gives the firm significant leverage, pressuring the Novavax board to engage with its proposals more seriously or risk further erosion of investor confidence.

Boardroom Battles and Broader Trends

The showdown at Novavax is emblematic of a wider trend in corporate governance. Shareholders, particularly large institutional and activist funds, are increasingly unwilling to rubber-stamp board decisions, especially on executive pay and director elections. They are demanding a clearer link between compensation and genuine, long-term value creation.

The fact that Novavax's pay package received such strong opposition despite support from proxy advisors highlights this shift. Investors are conducting their own due diligence and are prepared to defy standard recommendations when they feel a company's leadership is not aligned with their interests. Shah Capital's call to slash the board from eight to five members and rein in what it deems "excessive administrative/consulting costs" speaks directly to this demand for leaner, more effective governance.

In response to the activist pressure, Novavax has maintained that it is executing a growth strategy that will deliver long-term value, pointing to its partnerships and R&D pipeline. While the company's official filings acknowledged the vote counts, it has yet to issue a direct public response to Shah's characterization of the results as a "wake-up call." The board now finds itself at a critical crossroads: it can either dismiss the vote as minority dissent or treat it as a serious mandate for change. How Novavax leadership navigates this pressure in the coming months will be critical in determining its ability to restore credibility with investors and fully capitalize on its promising vaccine science.